Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
التنسيق: مقال
اللغة:English
منشور في: Elsevier 2023-08-01
سلاسل:Journal of Allergy and Clinical Immunology: Global
الموضوعات:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
الوصول للمادة أونلاين:http://www.sciencedirect.com/science/article/pii/S277282932300053X

الانترنت

http://www.sciencedirect.com/science/article/pii/S277282932300053X

مواد مشابهة